Repeatability of choroidal thickness measurements assessed with swept-source optical coherence tomography in healthy and diabetic individuals by Abadía, B. et al.
REPEATABILITY OF CHOROIDAL
THICKNESS MEASUREMENTS ASSESSED
WITH SWEPT-SOURCE OPTICAL
COHERENCE TOMOGRAPHY IN
HEALTHY AND DIABETIC INDIVIDUALS
BEATRIZ ABADÍA, MD, PHD,* PILAR CALVO, MD, PHD,*† FRANCISCO BARTOL-PUYAL, MD,*
GUAYENTE VERDES, MD, PHD,‡ INÉS SUÑÉN, MD,† ANTONIO FERRERAS, MD, PHD*†
Purpose: To assess the intrasession repeatability of choroidal thickness measurements
obtained using swept-source optical coherence tomography in Type 2 diabetic (T2D)
patients and healthy controls.
Methods: This was a single-center, prospective, observational, cross-sectional study
with consecutive inclusion of 33 healthy subjects and 43 T2D patients. Subjects underwent
three consecutive swept-source optical coherence tomography scans in a single session.
After automatic delineation of the choroid, subfoveal choroidal thickness, and thickness at
500-mm intervals up to 2,500 mm nasal and temporal from the fovea were measured using
the software caliper by the same operator. Intraclass correlation coefficients (ICCs), coef-
ficients of variation, and test-retest variability were calculated.
Results: Mean subfoveal choroidal thickness in healthy subjects and in T2D patients
was 229.97 ± 79.9 and 192.67 ± 74.3 mm, respectively (P = 0.013). All intrasession intra-
class correlation coefficients were higher than 0.95 and 0.99, respectively. Coefficients of
variations were less than 4.4% and 1.8%, respectively. Test-retest variability ranged from
0.76 mm to 11.12 mm and 0.64 mm to 6.29 mm, respectively. No significant differences were
found in the intrasession repeatability of any choroidal measurement between healthy
subjects and T2D patients.
Conclusion: Swept-source optical coherence tomography provided excellent intra-
session repeatability of choroidal thickness measurements in healthy subjects and T2D
patients.
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Optical coherence tomography (OCT) has rapidlyevolved since its development in the early 1990s,
with ongoing improvements allowing for a better
understanding of ocular structures such as the optic
nerve, retina, and choroid.1 Continuous improvement
has been made to the scanning speed, sensitivity, and
depth for generating high-resolution cross-sectional
imaging of OCT, providing the opportunity to explore
this vascular tissue in better detail. Enhanced depth
imaging (EDI) spectral domain (SD) OCT system2–4
and more recently the incorporation of technology for
deep range image swept-source (SS) OCT has permit-
ted a more precise study of the choroid.5 Swept-source
optical coherence tomography uses a longer-
wavelength light source than SD-OCT, which allows
deeper penetration in the choroid than EDI SD-OCT
and provides better layer segmentation of the sclero-
choroid interface, without affecting resolution in the
retina.6,7 Moreover, the automatic segmentation soft-
ware of SS-OCT makes the measurements more accu-
rate and reproducible.8 Although Adhi et al9 reported no
differences in macular choroidal thickness measurements
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between SS- and EDI SD-OCT, Tan et al10 found that
manual segmentation of SD-OCT may differ by more
than 50 mm compared with the automated segmentation
of SS-OCT.
The better visualization has led to more intensive
investigations of this vascular structure that seems to
have a significant role in different retinal patholo-
gies.11 Diabetic retinopathy (DR) is a neurovascular
disease with a high prevalence and high socioeco-
nomic impact. Recent studies revealed associations
between an abnormal choroidal thickness and diabe-
tes.12–18 Evaluating choroidal changes may help clini-
cians to make better therapeutic decisions and to
monitor the effect of treatments. For example, recent
studies in patients with wet age-related macular degen-
eration and diabetes reported that choroidal thickness
may predict the response to antiangiogenic agents.19,20
Assessment of the accuracy of the measurements to
compare them over time and differentiate true ana-
tomic changes from the actual variability of the meas-
urements is thus critical. Although other studies have
evaluated the choroidal thickness SS-OCT’s reproduc-
ibility in healthy eyes,21–25 eyes of diabetic patients
have not been evaluated. The purpose of this study
was to evaluate the repeatability of choroidal thickness
measurements using SS-OCT in healthy individuals
and in patients with Type 2 diabetes (T2D).
Material and Methods
The Clinical Research Ethics Committee of Aragón
(CEICA) approved the study protocol, which adhered
to the tenets of the Declaration of Helsinki. This study
was performed in a retrospective observational cross-
sectional manner. All individuals from December
2015 to July 2016 who met the inclusion criteria and
provided written informed consent were consecutively
recruited for the study. Healthy patients were selected
from healthy volunteers and study-naive patients with
T2D were recruited from the Retina Unit of Miguel
Servet University Hospital at Zaragoza (Spain).
Subjects were eligible if they were adults with
a refractive error of less than 6 spherical diopters
and/or 2 diopters cylinder, axial length #26 mm, and
euthyroid. Exclusion criteria included opacity of the
optical media that could interfere with the quality of
the OCT (signal/noise ratio ,70/100), preexisting ret-
inal, choroidal, or optic nerve pathology, previous ocu-
lar treatment with laser (focal or panretinal
photocoagulation) or intravitreal agents, inflammatory
diseases or active or recent infection (ocular and/or
systemic), systemic treatment with corticosteroids,
immunosuppressive drugs or biologic therapies, preg-
nancy, and puerperium.
A full ophthalmologic examination was performed
in all patients including clinical history, best-corrected
visual acuity (BCVA, decimal scale), examination of
the anterior segment using a slit-lamp, Goldmann
applanation tonometry, and ophthalmoscopy of the
posterior segment. Optical biometry (IOLMaster 500,
Carl Zeiss Meditec AG, Jena, Germany) was used to
measure axial length. In addition, a fasting blood
sample was obtained from an arm vein to determine
plasma glucose levels.
Diabetic Retinopathy Grading
Naive T2D patients were diagnosed based on the
criteria of the American Diabetes Association,26 and all
were negative for anti-glutamic acid decarboxylase anti-
body. This group was divided according to the degree of
DR into five subgroups based on the Diabetic Retinop-
athy Severity Scale criteria27: no DR, mild nonprolifer-
ative DR (NPDR), moderate NPDR, severe NPDR, and
proliferative DR. Diabetic macular edema was assessed
by clinical examination and SS-OCT imaging.
Choroidal Thickness Measurements Using Swept-
Source Optical Coherence Tomography
Each SS-OCT (Topcon 3D deep range imaging
OCT Triton [plus]; Topcon Corporation, Tokyo,
Japan) scan comprised a 12-mm horizontal line scan
protocol centered between the optic disc and the fovea
with 1,024 A-scans for each 96 B-scan. The images
were obtained by an experienced technician after pupil
dilation with tropicamide 1% and phenylephrine
2.5% and performed at the same time of day in all
patients (between 4:00 PM and 7:00 PM). Scan acquisi-
tion was realized with low ambient light looking at the
internal fixation point to obtain the best alignment.
Subjects underwent three consecutive SS-OCT scans
in a single session. Between scans, patients sat back
away from the device and rested at least for 2 minutes.
The on-board segmentation algorithm (Topcon
Advanced Boundary Segmentation; TABS) was used
to automatically segment the choroidal layer from the
outer edge of the hyper-reflective retinal pigment epi-
thelial line to the inner edge of the sclera. After auto-
matic delineation of the choroid on the B-scan, 11
thickness measurements were manually obtained using
a caliper: 5 measurements nasal (N1, N2, N3, N4, and
N5) and temporal (T1, T2, T3, T4, and T5) to the
fovea were obtained at 500-mm intervals along with
the subfoveal (SF) measurement (Figures 1 and 2).
Each location was measured by the same operator
within 2 weeks. The operator was masked to the pa-
tients’ identity and clinical history. Automated seg-
mentation errors of choroidal layers were defined as
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instances in which the software determined choroidal
boundaries that clearly deviated from the true anatom-
ical boundaries. The automated segmentation errors
were manually corrected by the same experienced
observer. Scans with a lower quality (,70/100) were
discarded.
Statistical Analysis
Statistical analyses were performed using IBM
SPSS (version 23.0; IBM Corporation, Somers, NY)
statistical software. All the variables followed a normal
distribution as verified by the Kolmogorov–Smirnov
test. For description of the clinical characteristics of
the groups, the mean and standard deviation were
used. The intraclass correlation coefficient (ICC),
coefficient of variation (COV), and test-retest variabil-
ity (TRTV) were calculated for each choroidal
thickness.
Intraclass correlation coefficient is a statistic that
condenses the reproducibility of a parameter for
a given group of subjects. A large ICC suggests small
fluctuations among repeated measurements in the same
individual. The ICC value can range from 0 to
a maximum of 1.
Coefficients of variation were calculated as the
standard deviation divided by the average of the
measured values expressed as a percentage. Test-
retest variability in choroidal thickness was calculated
as two times the standard deviation of the three
repeated measurements for each choroidal thickness
variable.
Differences between quantitative parameters were
tested by Student’s t test, and qualitative variables
were compared by the chi-square test. The mean of
the three scans was used for comparison of the cho-
roidal measurements. For all analyses, P , 0.05 was
considered statistically significant.
Fig. 1. Choroidal measure-
ments obtained on the 3 differ-
ent captured scans at SF level,
and at 500-mm intervals up to
2,500 mm nasal and temporal
from the fovea in a healthy
individual.
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Results
Overall, 110 eyes of 76 Caucasian individuals were
included in this prospective study. All participants
completed the study. The healthy group comprised 50
eyes of 33 patients, and the T2D group included 60
eyes of 43 patients: 7 eyes without DR, 13 eyes with
mild NPDR, 32 eyes with moderate NPDR, 5 eyes
with severe NPDR, and 3 eyes with proliferative DR.
Diabetic macular edema was diagnosed in 30 eyes
(50%). Mean patient age in the healthy and T2D
groups was 68.02 ± 8.8 and 66.28 ± 7.8 years, respec-
tively (Table 1). Overall, no statistically significant
differences were detected between healthy controls
and the T2D group regarding age, intraocular pressure,
quality of scan, accuracy of automatic layer segmen-
tation, or laterality. The groups differed significantly
regarding sex, BCVA, and choroidal thickness in SF,
N1, T1, T2, T3, T4, and T5 measurements.
Table 2 shows ICC and 95% confidence interval
(CI), COV, and TRTV in the whole sample. All ICCs
were higher than 0.98 (P , 0.001) with a 95% CI
close to 1 in all positions. Coefficient of variation
was ,2% for all choroidal measurements, and the
maximum variability (TRTV) observed was 6.78 mm
in the N5 position.
In the healthy group, ICCs were excellent (.0.95;
P , 0.001) for all choroidal measurements (Table 3).
The SF choroidal thickness had the highest ICC
(1; 95% CI 1–1; P , 0.001) and the N5 choroidal
thickness exhibited the lowest ICC (0.965; 95% CI
0.944–0.979; P , 0.001). All COVs were under
4.5%, with the highest value (4.38%) in the N5 cho-
roidal measurement and the lowest (0.20%) in the SF
choroidal measurement. Test-retest variability ranged
from 0.76 mm to 11.12 mm. The lowest value corre-
sponded to the SF measurement and the highest to the
N5 position.
Fig. 2. Choroidal measure-
ments obtained on the 3 differ-
ent captured scans at SF level,
and at 500-mm intervals up to
2,500 mm nasal and temporal
from the fovea in a diabetic
patient with diabetic macular
edema.
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Intrasession repeatability of all choroidal thickness
measurements in the T2D group is shown in Table 4.
Intraclass correlation coefficients ranged from 0.981
(N2) to 1 (SF; P , 0.001). Coefficients of variation
ranged from 0.17% (SF) to 1.79% (N2), and TRTV
ranged from 0.64 mm (SF) to 6.29 mm (N2).
No significant difference (P . 0.05) was found in
the intratest repeatability of any choroidal measure-
ment between healthy controls and T2D patients.
Discussion
In recent years, investigations have begun to focus
on the role played by the choroid in DR.15 This
increase in interest is related to the development of
improvements in OCT, because of technology such
as EDI, and more recently to SS-OCT. These advances
have brought faster scanning speeds and a reduction in
artefacts that allow for better visualization of this
Table 1. Clinical Characteristics in Healthy Subjects and Type 2 Diabetic Patients
Healthy Subjects T2D Patients P
Age (years) 68.02 ± 8.8 66.28 ± 7.8 0.28*
BCVA (Snellen) 0.88 ± 0.2 0.69 ± 0.3 ,0.001*
IOP (mmHg) 16.08 ± 2.4 16.85 ± 3.6 0.17*
Plasma glucose (mg/dL) 94.64 ± 12.5 143.07 ± 45.8 ,0.001*
Quality scan 94.34 ± 4.4 93.13 ± 5.2 0.20*
Choroidal thickness SF (mm) 229.97 ± 79.9 192.67 ± 74.3 0.013*
Choroidal thickness N1 (mm) 228.83 ± 81.4 191.43 ± 75.3 0.014*
Choroidal thickness N2 (mm) 218.11 ± 79.6 189.04 ± 78.1 0.06*
Choroidal thickness N3 (mm) 197.92 ± 81.1 171.04 ± 75.6 0.08*
Choroidal thickness N4 (mm) 173.56 ± 81.7 149.74 ± 70.0 0.10*
Choroidal thickness N5 (mm) 150.00 ± 75.4 129.42 ± 67.2 0.13*
Choroidal thickness T1 (mm) 225.08 ± 73.0 189.51 ± 67.4 0.009*
Choroidal thickness T2 (mm) 222.95 ± 72.4 188.61 ± 68.7 0.012*
Choroidal thickness T3 (mm) 223.53 ± 71.5 187.78 ± 68.3 0.009*
Choroidal thickness T4 (mm) 218.19 ± 69.5 180.37 ± 63.0 0.003*
Choroidal thickness T5 (mm) 213.23 ± 69.3 173.94 ± 63.1 0.002*
Female-male (%) 39-11 (78%–22%) 21-39 (35%–65%) ,0.001†
Right/left (%) 26-24 (52%) 31-29 (51.7%) 0.97†
Accurate segmentation 45-5 (90%) 50-10 (80%) 0.31†
n 50 60
Choroidal thicknesses and quality scan are expressed as the mean of the three scans. Inaccurate segmentation was considered when
the three scans had automated segmentation errors. Significant differences are highlighted in bold print. Data are expressed in mean ±
SD, except sex, laterality, accuracy of layer segmentation, and number of cases.
*Student’s t test.
†Chi-square test.
BCVA, best-corrected visual acuity; IOP, intraocular pressure; n, number of cases; N1, nasal 500 mm from fovea; N2, nasal 1,000 mm
from the fovea; N3, nasal 1,500 mm from the fovea; N4, nasal 2,000 mm from the fovea; N5, nasal 2,500 mm from the fovea; T1, temporal
500 mm from the fovea; T2, temporal 1,000 mm from the fovea; T3, temporal 1,500 mm from the fovea; T4, temporal 2,000 mm from the
fovea; T5, temporal 2,500 mm from the fovea.
Table 2. Intrasession Repeatability of Choroidal Thicknesses in the Whole Sample
ICC ICC, 95% Lower Bound ICC, 95% Upper Bound P COV ± SD (%) TRTV ± SD (mm)
SF 1 1 1 ,0.001 0.18 ± 0.3 0.69 ± 1.2
N1 0.995 0.993 0.996 ,0.001 0.96 ± 3.0 3.50 ± 11.2
N2 0.984 0.978 0.988 ,0.001 1.79 ± 5.1 6.40 ± 19.6
N3 0.995 0.993 0.996 ,0.001 1.39 ± 3.2 4.54 ± 10.6
N4 0.995 0.993 0.996 ,0.001 1.45 ± 3.7 4.10 ± 10.5
N5 0.982 0.975 0.987 ,0.001 2.75 ± 7.6 6.78 ± 18.3
T1 0.999 0.999 0.999 ,0.001 0.76 ± 1.2 2.65 ± 3.7
T2 0.985 0.979 0.989 ,0.001 1.21 ± 3.6 5.39 ± 17.1
T3 0.994 0.992 0.996 ,0.001 1.12 ± 3.9 3.73 ± 10.3
T4 0.987 0.983 0.991 ,0.001 1.51 ± 4.6 5.29 ± 14.6
T5 0.985 0.980 0.996 ,0.001 1.43 ± 5.8 4.65 ± 16.1
N1, nasal 500 mm from the fovea; N2, nasal 1,000 mm from the fovea; N3, nasal 1,500 mm from the fovea; N4, nasal 2,000 mm from the
fovea; N5, nasal 2,500 mm from the fovea; SD, standard deviation; T1, temporal 500 mm from the fovea; T2, temporal 1,000 mm from the
fovea; T3, temporal 1,500 mm from the fovea; T4, temporal 2,000 mm from the fovea; T5, temporal 2,500 mm from the fovea.
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structure and therefore a better understanding of this
vascular tissue.11
Knowledge of the behavior of the choroid in healthy
subjects will elucidate the changes of the choroid in
diabetic patients. Previous studies reported that the
choroid undergoes significant changes throughout the
day, with age and with axial length, in healthy
individuals.28–32 In diabetic patients, choroid thickness
seems to decrease,13–17 although other authors have
reported the opposite finding (thicker choroid in dia-
betic patients).12 Panphotocoagulation and antiangio-
genic treatment may decrease choroidal thickness over
the long-term12,33–35 and choroidal thickness may pre-
dict the response to antiangiogenic treatment, where
a greater thickness predicts a better anatomic and func-
tional result after the injection.20
Overall, T2D patients presented with a thinner
choroid than healthy subjects. In both groups, meas-
urements revealed a similar pattern: the choroid was
thickest in the SF location, followed by temporal and
nasal measurements close to the SF area. The choroid
was thinner in the temporal and nasal measurements
far away from the SF area, and thinnest in the nasal
choroid near the optic disc. Our results agree with
previous reports by Regatieri et al, Querques et al, and
Esmaeelpour et al that diabetic patients have a thinner
choroid.14–16
Variability of measurements for any test may be
critical for accurate diagnosis, follow-up, and assess-
ment of the response to treatment. Repeatability of
choroidal measurements can improve our understand-
ing of the detection, progression, and response to
treatment of DR, where the choroid may have an
important role. To interpret these changes in choroidal
thickness it is crucial to understand the test variability.
We found that choroidal measurements acquired with
SS-OCT had low variability (high ICCs and low
COVs) for healthy and diabetic eyes.
To the best of our knowledge, this study is the first
to report the intratest repeatability of 11 choroidal
measurements with SS-OCT in a large population of
healthy and diabetic patients. The results of
Table 3. Intrasession Repeatability of Choroidal Thicknesses in Healthy Subjects
ICC ICC, 95% Lower Bound ICC, 95% Upper Bound P COV ± SD (%) TRTV ± SD (mm)
SF 1 1 1 ,0.001 0.20 ± 0.4 0.76 ± 1.3
N1 0.999 0.999 1 ,0.001 0.72 ± 1.0 2.89 ± 2.9
N2 0.986 0.977 0.991 ,0.001 1.80 ± 4.9 6.53 ± 18.2
N3 0.990 0.985 0.994 ,0.001 2.01 ± 4.6 6.85 ± 15.2
N4 0.991 0.985 0.994 ,0.001 2.16 ± 5.3 6.25 ± 15.2
N5 0.965 0.944 0.979 ,0.001 4.38 ± 11.0 11.12 ± 26.4
T1 0.998 0.957 0.999 ,0.001 0.97 ± 1.6 3.40 ± 4.7
T2 0.968 0.950 0.981 ,0.001 1.88 ± 5.2 8.74 ± 24.8
T3 0.988 0.981 0.993 ,0.001 1.47 ± 5.7 4.78 ± 14.9
T4 0.974 0.959 0.984 ,0.001 2.29 ± 6.7 8.07 ± 21.1
T5 0.970 0.952 0.982 ,0.001 2.30 ± 8.8 7.81 ± 23.5
N1, nasal 500 mm from the fovea; N2, nasal 1,000 mm from the fovea; N3, nasal 1,500 mm from the fovea; N4, nasal 2000 mm from the
fovea; N5, nasal 2,500 mm from the fovea; SD, standard deviation; T1, temporal 500 mm from the fovea; T2, temporal 1,000 mm from the
fovea; T3, temporal 1,500 mm from the fovea; T4, temporal 2,000 mm from the fovea; T5, temporal 2,500 mm from the fovea.
Table 4. Intrasession Repeatability of Choroidal Thicknesses in T2D Patients
ICC ICC, 95% Lower Bound ICC, 95% Upper Bound P COV ± SD (%) TRTV ± SD (mm)
SF 1 1 1 ,0.001 0.17 ± 0.3 0.64 ± 1.2
N1 0.990 0.984 0.993 ,0.001 1.17 ± 3.0 4.02 ± 15.0
N2 0.981 0.972 0.988 ,0.001 1.79 ± 5.4 6.29 ± 20.9
N3 0.999 0.999 1 ,0.001 0.86 ± 1.0 2.62 ± 2.9
N4 0.999 0.999 1 ,0.001 0.85 ± 1.0 2.30 ± 2.4
N5 0.999 0.998 0.999 ,0.001 1.39 ± 1.5 3.17 ± 3.6
T1 0.999 0.999 1 ,0.001 0.59 ± 0.7 2.03 ± 2.3
T2 0.999 0.998 0.999 ,0.001 0.66 ± 0.8 2.60 ± 3.5
T3 0.999 0.998 0.999 ,0.001 0.84 ± 1.1 2.85 ± 3.4
T4 0.999 0.998 0.999 ,0.001 0.86 ± 1.0 2.98 ± 3.3
T5 0.999 0.999 1 ,0.001 0.71 ± 0.9 2.01 ± 2.2
N1, nasal 500 mm from the fovea; N2, nasal 1,000 mm from the fovea; N3, nasal 1,500 mm from fovea; N4, nasal 2,000 mm from the
fovea; N5, nasal 2,500 mm from the fovea; SD, standard deviation; T1, temporal 500 mm from the fovea; T2, temporal 1,000 mm from the
fovea; T3, temporal 1,500 mm from the fovea; T4, temporal 2,000 mm from the fovea; T5, temporal 2,500 mm from the fovea.
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intraobserver repeatability were excellent. We ob-
tained ICCs values close to one in all choroidal
locations in the whole sample and in both healthy
and diabetic groups.
In the healthy group, choroidal thickness at N5
(2,500 mm from the fovea) exhibited the worst repeat-
ability values. This may be due to the presence of the
optic nerve in the nasal zone, which could make mea-
suring more difficult, and also to the decrease in cho-
roidal thickness peripherally. In T2D patients,
choroidal thickness at N2 (1,000 mm from the fovea)
showed the worst repeatability values. Although no
significant differences were found in the intratest
repeatability between healthy controls and T2D pa-
tients, diabetics tended to have better repeatability val-
ues than healthy controls. This could be due to the
thinner choroidal thicknesses in diabetics, which
would decrease the range of change of the same
variable.
Previous studies evaluated the reproducibility of
choroidal thickness measurements using SD-OCT,
especially in healthy and young populations21–
25,36,37; few of these studies, however, were based on
SS-OCT technology.38,39 Shao et al25 studied the intra-
observer reproducibility of 21 healthy eyes (mean age,
63.1 ± 10.6 years) with EDI SD-OCT. They scanned
10 times with 1-minute breaks between each examina-
tion. They found an ICC of 1 (P , 0.001) and a mean
COV of 0.85 ± 1.48%. Mansuri et al39 studied intra-
observer reproducibility with SS-OCT in 54 eyes of 27
healthy subjects (mean age, 36.6 ± 10.4 years) with 4
different scanning protocols, one of which was the
same as ours, a 12-mm horizontal line centered on
the fovea in undilated patients. Each scan protocol
was repeated three times consecutively on the same
visit, similar to our study, and the ICC was 0.93
(95% CI: 0.91–0.95). Sim et al37 studied reproducibil-
ity in a cohort of 51 eyes of 51 patients with T2D
(mean age: 60.1 ± 13.6 years) using SD-OCT, a man-
ual segmentation made by 2 different graders, and
calculation of mean choroidal thicknesses within Early
Treatment Diabetic Retinopathy Study (ETDRS)
areas. They found an ICC of 0.97 (95% CI: 0.94–
0.99). Our results confirmed the low variability of
choroidal thickness measurements acquired with SD-
OCT and SS-OCT.
A strength of our study is that this was a prospective
study of 11 choroidal measurements with SS-OCT in
a large sample, including healthy and T2D patients.
Another strength was that we used automatic detection
and segmentation software to delineate choroidal
structures, which theoretically allows for a more
accurate and objective analysis, although errors of
segmentation had to be manually corrected in 10% to
20% of images. A limitation of this study was that we
did not perform vertical or radial scans and, conse-
quently, our results are based only on the horizontal
axis measurements. Another limitation is that the T2D
group was characterized by different stages of DR,
which limits any conclusion on choroidal differences
between the two groups. In addition, clinicians should
take into account that only good-quality scans were
included in the statistical analysis, which might have
influenced the upper and lower limits, as real-world
practice includes patients with cataracts, poor fixation,
and larger refractive errors. Further studies using SS-
OCT are needed to elucidate the differences in
choroidal thickness between diabetic and healthy eyes.
In conclusion, intrasession repeatability of choroidal
thickness measurements in healthy and T2D patients
obtained with SS-OCT was excellent. Clinicians must
take into account the repeatability of every parameter
to differentiate normal variability from significant
clinical changes.
Key words: choroid, choroidal thickness, diabetic
retinopathy, repeatability, swept-source OCT.
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